{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:29:20Z","timestamp":1790998160462,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005627","name":"Thrasher Research Fund","doi-asserted-by":"publisher","award":["R01DA039962"],"award-info":[{"award-number":["R01DA039962"]}],"id":[{"id":"10.13039\/100005627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM125507"],"award-info":[{"award-number":["P20GM125507"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039962"],"award-info":[{"award-number":["R01DA039962"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["L40DA042434"],"award-info":[{"award-number":["L40DA042434"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA045224"],"award-info":[{"award-number":["K01DA045224"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.amepre.2020.03.022","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T07:43:52Z","timestamp":1590047032000},"page":"e125-e133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Opioid Use Disorder Treatment Facilities With Programs for Special Populations"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-6199","authenticated-orcid":false,"given":"Scott E.","family":"Hadland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5695-081X","authenticated-orcid":false,"given":"Victoria A.","family":"Jent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Alinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D.L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia M.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"329","key":"10.1016\/j.amepre.2020.03.022_bib0001","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999-2017","author":"Hedegaard","year":"2018","journal-title":"NCHS Data Brief"},{"issue":"1","key":"10.1016\/j.amepre.2020.03.022_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"10.1016\/j.amepre.2020.03.022_bib0003","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11","volume":"34","author":"Dick","year":"2015","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"10.1016\/j.amepre.2020.03.022_bib0004","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jama.2012.234","article-title":"Association of mental health disorders with prescription opioids and high-risk opioid use in U.S. veterans of Iraq and Afghanistan","volume":"307","author":"Seal","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.amepre.2020.03.022_bib0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/10550887.2013.795467","article-title":"Comorbid posttraumatic stress disorder and opiate addiction: a literature review","volume":"32","author":"Fareed","year":"2013","journal-title":"J Addict Dis"},{"key":"10.1016\/j.amepre.2020.03.022_bib0006","series-title":"Opioid Use and Opioid Use Disorder in Pregnancy","year":"2017"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0007","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/08897077.2018.1488336","article-title":"Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states","volume":"40","author":"Patrick","year":"2019","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0008","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.amepre.2020.03.022_bib0010","unstructured":"Behavioral health treatment services locator. Substance Abuse and Mental Health Services Administration (SAMHSA). https:\/\/findtreatment.samhsa.gov\/. Updated 2018. Accessed October 5, 2018."},{"key":"10.1016\/j.amepre.2020.03.022_bib0011","series-title":"CDC WONDER","year":"2018"},{"key":"10.1016\/j.amepre.2020.03.022_bib0012","unstructured":"National Center for Veterans Analysis and Statistics. Veteran population table. U.S. Department of Veterans Affairs. www.va.gov\/vetdata\/veteran_population.asp. Updated 2018. Accessed October 22, 2018."},{"key":"10.1016\/j.amepre.2020.03.022_bib0013","series-title":"Social explorer, U.S. Census Bureau","year":"2016"},{"key":"10.1016\/j.amepre.2020.03.022_bib0014","series-title":"Centers for Disease Control and Prevention, National Center for Health Statistics","year":"2017"},{"key":"10.1016\/j.amepre.2020.03.022_bib0015","unstructured":"U.S. county prescribing rate maps, 2018. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxcounty2018.html. Updated 2018. Accessed October 22, 2018."},{"key":"10.1016\/j.amepre.2020.03.022_bib0016","unstructured":"MUA find. Health Resources and Services Administration. https:\/\/data.hrsa.gov\/tools\/shortage-area\/mua-find. Updated 2018. Accessed October 2, 2018."},{"issue":"1","key":"10.1016\/j.amepre.2020.03.022_bib0017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of U.S. physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Ann Fam Med"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0018","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2018.1509251","article-title":"Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration","volume":"39","author":"Valenstein-Mah","year":"2018","journal-title":"Subst Abus"},{"key":"10.1016\/j.amepre.2020.03.022_bib0019","series-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.amepre.2020.03.022_bib0020","series-title":"Encyclopedia of GIS","article-title":"Spatial weights matrix","author":"Zhou","year":"2008"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1538-4632.1992.tb00261.x","article-title":"The analysis of spatial association by use of distance statistics","volume":"24","author":"Getis","year":"1992","journal-title":"Geogr Anal"},{"issue":"2","key":"10.1016\/j.amepre.2020.03.022_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.2517-6161.1948.tb00012.x","article-title":"The interpretation of statistical maps","volume":"10","author":"Moran","year":"1948","journal-title":"J R Stat Soc Series B (Methadol)"},{"key":"10.1016\/j.amepre.2020.03.022_bib0023","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13669-016-0168-9","article-title":"Caring for pregnant women with opioid use disorder in the USA: expanding and improving treatment","volume":"5","author":"Saia","year":"2016","journal-title":"Curr Obstet Gynecol Rep"},{"issue":"1","key":"10.1016\/j.amepre.2020.03.022_bib0024","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jrh.12307","article-title":"Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update","volume":"35","author":"Andrilla","year":"2019","journal-title":"J Rural Health"},{"issue":"2","key":"10.1016\/j.amepre.2020.03.022_bib0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","article-title":"Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps","volume":"39","author":"Wyse","year":"2018","journal-title":"Subst Abus"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1748-0361.2010.00294.x","article-title":"Use of psychotherapy by rural and urban veterans","volume":"26","author":"Cully","year":"2010","journal-title":"J Rural Health"},{"issue":"11","key":"10.1016\/j.amepre.2020.03.022_bib0027","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"8","key":"10.1016\/j.amepre.2020.03.022_bib0028","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"8","key":"10.1016\/j.amepre.2020.03.022_bib0029","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"6","key":"10.1016\/j.amepre.2020.03.022_bib0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0031","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.whi.2016.12.008","article-title":"Characterization of U.S. state laws requiring health care provider reporting of perinatal substance use","volume":"27","author":"Jarlenski","year":"2017","journal-title":"Womens Health Issues"},{"issue":"2","key":"10.1016\/j.amepre.2020.03.022_bib0032","first-page":"193","article-title":"Criminal charges for child harm from substance use in pregnancy","volume":"45","author":"Angelotta","year":"2017","journal-title":"J Am Acad Psychiatry Law"},{"issue":"3","key":"10.1016\/j.amepre.2020.03.022_bib0033","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4070","article-title":"Committee on Substance Use and Prevention. A public health response to opioid use in pregnancy","volume":"139","author":"Patrick","year":"2017","journal-title":"Pediatrics"},{"issue":"10051","key":"10.1016\/j.amepre.2020.03.022_bib0034","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(16)31573-2","article-title":"How the paediatric workforce can address the opioid crisis","volume":"388","author":"Hadland","year":"2016","journal-title":"Lancet"}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379720301781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379720301781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:34:20Z","timestamp":1777574060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379720301781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0749379720301781"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2020.03.022","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid Use Disorder Treatment Facilities With Programs for Special Populations","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2020.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}